Tempus AI Shares See Volume To The Upside; Co Surpasses 500 Research Publications
Author: Benzinga Newsdesk | July 10, 2024 09:31am
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged work, comprised of:
- 143 peer-reviewed articles, of which 106 were Tempus-authored;
- 291 poster presentations based on clinical and research data presented at major scientific conferences; and
- 31 oral presentations at scientific meetings such as the American Society of Clinical Oncology (ASCO) Annual Meeting, San Antonio Breast Cancer Symposium (SABCS), Society for Immunotherapy of Cancer (SITC) Annual Meeting, and American Heart Association's Scientific Sessions.
Posted In: TEM